Equities Analysts Offer Predictions for Abeona Therapeutics Inc’s Q3 2024 Earnings (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at HC Wainwright lowered their Q3 2024 EPS estimates for shares of Abeona Therapeutics in a research note issued on Wednesday, August 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.26) EPS, Q1 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($1.19) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06).

A number of other analysts have also recently issued reports on the company. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Stifel Nicolaus started coverage on shares of Abeona Therapeutics in a research note on Thursday, May 30th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Cantor Fitzgerald decreased their target price on shares of Abeona Therapeutics from $28.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, May 16th.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.00 on Friday. The business has a 50 day moving average price of $4.73 and a two-hundred day moving average price of $5.57. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a market cap of $204.82 million, a price-to-earnings ratio of -1.56 and a beta of 1.59.

Institutional Trading of Abeona Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 2,434 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Abeona Therapeutics in the 1st quarter valued at $91,000. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics in the 4th quarter worth about $199,000. Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $1,732,000. Finally, Renaissance Technologies LLC lifted its holdings in Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.